GUILHERME NADER MARTA
Projetos de Pesquisa
Unidades Organizacionais
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
36 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 36
- Trends in Melanoma Mortality in Brazil: A Registry-Based Study(2020) MARTA, Guilherme Nader; MUNHOZ, Rodrigo Ramella; TEIXEIRA, Monica La Porte; WALDVOGEL, Bernadette Cunha; CAMARGO, Veridiana Pires de; FEHER, Olavo; SANCHES, Jose AntonioPURPOSE A substantial increase in melanoma incidence has been consistently observed worldwide over the past decades. However, melanoma mortality rates have remained stable or declined over the past years in most regions. Given the paucity of melanoma mortality data for different Brazilian regions, we sought to describe melanoma mortality trends in southeastern Brazil and their relationship with demographic variables. MATERIALS AND METHODS A cross-sectional registry-based analysis was conducted to describe melanoma mortality trends in the state of SAo Paulo, Brazil, from 1996 to 2016. Demographic information from melanoma-related death records, including sex and age, was collected from the FundacAo Sistema Estadual de Analise de Dados database. The annual percentage change (APC) was calculated to identify mortality trends over the period. RESULTS An increasing melanoma mortality trend was detected among males, regardless of age (APC, 1.72%; P < .001), and was more pronounced for men >= 60 years old (APC, 2.63%; P < .001). Melanoma mortality rates have also increased for patients >= 60 years old, regardless of sex (APC, 1.11%; P < .001). A non-statistically significant increase in the overall melanoma mortality rate was observed over the 20-year period analyzed (APC, 0.36%; P = .4). CONCLUSION Our data suggest a stable melanoma mortality over the past two decades for the overall population studied; however, a significant increase in melanoma mortality rates has been demonstrated among males and in the population >= 60 years old, emphasizing the need to implement prevention strategies and expand access to effective therapies for this population. (c) 2020 by American Society of Clinical Oncology
- Patterns of post-operative radiotherapy in breast cancer patients after neoadjuvant chemotherapy(2017) LOPES, K. M.; FREITAS, T. B. De; CARVALHO, H. A.; PEREIRA, A. A.; SILVA, S. B.; STUART, S. R.; MANO, M. S.; FILASSI, J. R.; MARTA, G. N.
- Trends in melanoma mortality in Brazil: A 20-year registry-based study(2020) MARTA, G. Nader; MUNHOZ, R. Ramella; TEIXEIRA, M. La Porte; WALDVOGEL, B. Cunha; CAMARGO, V. P. D.; NARDO, M.; BARBOSA, C. Chaul de Lima; FEHER, O.; HOFF, P. M.; SANCHES, J. A.
- Survival predictors in patients with head and neck cancer treated with surgical resection(2017) FRANCO, R. C. D. O.; MATOS, L. L. De; CASTRO JUNIOR, G. De; KULCSAR, M. A. V.; MARTA, G. N.
- Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?(2019) BONADIO, Renata Colombo; VELHO, Pedro Isaacsson; MARTA, Guilherme Nader; NARDA, Mirella; SOUZA, Manoel Carlos La; MUNIZ, David Q. B.; BEZERRA, Regis O. F.; BISPO, Raisa K. A.; FARAJ, Sheila F.; BASTOS, Diogo A.; DZIK, CarlosIntroduction: Non-clear cell renal cell carcinoma (nccRCC) and sarcomatoid renal cell carcinoma (sRCC) are underrepresented in clinical trials. Treatment approaches are frequently extrapolated from data of clear cell renal cell carcinoma, in which pazopanib is non-inferior to sunitinib. We aim to compare the effectiveness of first-line sunitinib and pazopanib for nccRCC and sRCC. Methods: We evaluated a retrospective cohort of patients with metastatic nccRCC and sRCC treated with first-line sunitinib or pazopanib at an academic cancer centre. Overall survival (OS), progression-free survival (PFS) and response rate were measured. Kaplan-Meier and log-rank analyses were used for time-to-event data. Cox regression was used for prognostic factors. Results: Fifty-three patients were included; 16 (30.1%) treated with sunitinib and 37 (69.9%) with pazopanib. Forty-six (86.8%) patients had nccRCC and 7 (13.2%) had sRCC. The majority had intermediate or poor International Metastatic Renal-Cell Carcinoma Database Consortium risk (93%). Median PFS was 6.6 months with sunitinib and 4.9 months with pazopanib (HR 1.75; P = 0.078). Treatment with pazopanib was associated with inferior OS in comparison with sunitinib (median OS: 30.4 months versus 8.7 months; HR 2.71, 95% CI 1.31-5.58, P = 0.007). These results were confirmed in subgroup analysis of patients with papillary, chromophobe and MiT family translocation histologies (median OS: 38.7 months versus 14.7 months; HR 3.16, 95% CI 1.20-8.29, P = 0.019). Unclassified and sarcomatoid histologies had inferior OS (median: 6.9 and 1.1 months, respectively) regardless of the treatment used. Conclusion: In this patient cohort, pazopanib was associated with inferior OS in comparison with sunitinib for metastatic nccRCC. Larger trials are ideally warranted to confirm these results.
- Assessment of quality of life in phase III clinical trials of radiation therapy in breast cancer(2017) MARTA, G. N.; MORAES, F. Y.; LEITE, E. T.; CHOW, E.; CELLA, D.; BOTTOMLEY, A.
conferenceObject Brazilian validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerized Adaptive Tests (CAT) Core(2020) SR., G. N. Marta; SAAD, E. D.; SOUZA, T. Y. T. de; NOBRE, A. Roxo; PEREIRA, A. P. A.; N, D. Rodrigues Ferreira; ASSO, R.; MIRANDA, F. A.; MARTA, G. N.; HANNA, S. A.; SILVA, M. F. Da; HOLZNER, B.; PETERSEN, M. A.- Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population(2018) VELHO, Pedro Isaacsson; NARDO, Mirella; SOUZA, Manoel Carlos Leonardde Azevedo; BONADIO, Renata R. C. Colombo; MARTA, Guilherrne Nader; MUNIZ, David Q. B.; BASTOS, Diogo Assed; DZIK, CarlosPurpose Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for metastatic clear cell renal cell carcinoma (ccRCC). The Brazilian public health system diverges from the randomized clinical trials in the availability of first and subsequent lines of treatment and in clinical and demographic characteristics of patients. Therefore, it is essential to describe the history of advanced ccRCC during and after TKI treatment in this population. Methods We performed a retrospective analysis of patients with advanced ccRCC treated with a first-line TKI (either sunitinib or pazopanib) between February 2009 and March 2017 in a single academic Brazilian cancer center (Instituto do Cancer do Estado de Sao Paulo). Results Of the 222 patients, 109 were treated with sunitinib and 113 with pazopanib. The median duration of treatment and overall survival (OS) were 6.4 and 15.2 months for sunitinib and 6.7 and 14.2 months for pazopanib, respectively. Discontinuation of treatment occurred secondarily to progressive disease or death in 64.2% of patients using sunitinib and in 54.8% of patients using pazopanib. Adverse events were responsible for discontinuation of treatment in 28.4% of patients in the sunitinib group and in 22.1% in the pazopanib group. According to Memorial Sloan-Kettering Cancer Center risk categories, the OS was 32.9 months, 15.9 months, and 8.1 months for low risk, intermediate risk, and poor risk, respectively (hazard ratio, 1.72; 95% CI, 1.13 to 2.26; P < .001). ConclusionThe use of TKI inhibitors as first-line treatment of metastatic RCC is effective and feasible in the Brazilian public health. However, the median OS of our population is considerably lower compared with the prospective trials that evaluated the same drugs. (C) 2018 by American Society of Clinical Oncology
- Quality of Life in Responders after Palliative Radiation Therapy for Painful Bone Metastases(2017) MENDEZ, L. C.; PADILHA, J. L.; LIMA, K. M.; CHOW, E.; MORAES, F. Y.; ESTEVES, M. D. P. E.; SILVA, M. F.; MARTA, G. N.
- Maltreatment and Emotion Recognition Among Brazilian Adolescents(2018) MARTA, Guilherme Rodrigues; DORETTO, Victoria Fogaca; SCIVOLETTO, SandraThe experience of maltreatment can impair child development, including changes in the process of emotions recognition, which may result in impairment of social interactions and behavioral disabilities. In order to measure the association between maltreatment and changes on emotion recognition among Brazilian adolescents, the Emotional Recognition Test on Human Faces (ERTHF) was applied to a sample of 50 adolescents who had suffered different intensities and types of abuse. The social and clinical characteristics of the participants were analyzed and, from ERTHF data, the accuracy and response time for the emotion recognition. Males were 60%, with mean age of 13 years and 3 months; 60% were living in shelters. Emotion recognition changes were associated with intensity and types of maltreatment. Physical neglect (48%) was associated with changes in neutral and negative emotions recognition. Emotional neglect (48%) and emotional abuse (46%) were associated with changes in both positive and negative emotions recognition. Physical abuse (38%) was associated with changes in positive emotion recognition only. False recognition of anger was the most common outcome of maltreatment, being associated with physical neglect (p = 0.015) and emotional neglect (p = 0.047). Our results point out to the need to add emotional and facial recognition's rehabilitation interventions to better attend the specific demands of maltreated children and to increase the chances of social and family reintegration.